Quantum Private Wealth LLC Sells 16,499 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Quantum Private Wealth LLC cut its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 26.5% during the 4th quarter, HoldingsChannel reports. The firm owned 45,775 shares of the medical research company’s stock after selling 16,499 shares during the period. Exact Sciences accounts for about 0.8% of Quantum Private Wealth LLC’s investment portfolio, making the stock its 21st biggest holding. Quantum Private Wealth LLC’s holdings in Exact Sciences were worth $2,572,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Huntington National Bank grew its position in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after buying an additional 352 shares during the period. RPg Family Wealth Advisory LLC bought a new stake in Exact Sciences during the third quarter worth about $34,000. Capital Performance Advisors LLP bought a new stake in Exact Sciences during the third quarter worth about $35,000. Asset Planning Inc bought a new position in shares of Exact Sciences during the fourth quarter valued at approximately $40,000. Finally, Modus Advisors LLC purchased a new position in shares of Exact Sciences during the fourth quarter valued at approximately $43,000. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Down 2.5 %

EXAS stock opened at $49.31 on Friday. The business’s 50-day moving average is $56.15 and its two-hundred day moving average is $60.18. The company has a market cap of $9.13 billion, a price-to-earnings ratio of -42.14 and a beta of 1.24. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on EXAS. Evercore ISI reduced their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Barclays assumed coverage on Exact Sciences in a report on Thursday, January 23rd. They set an “overweight” rating and a $70.00 price target for the company. Craig Hallum dropped their price target on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Benchmark restated a “buy” rating and set a $65.00 price objective on shares of Exact Sciences in a research note on Monday, January 13th. Finally, William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research note on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Exact Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $72.76.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.